7 results about "Tumor burden" patented technology

Embodiments of the present disclosure pertain to methods of assessing glioma in a subject by (1) receiving a plurality of measured biomarker levels of the subject; and (2) assessing glioma in the subject based on the measured biomarker levels by at least correlating differentially expressed levels of the measured biomarkers to at least one of (a) diagnosis of glioma, (b) progression of glioma, (c) treatment outcome, and / or (d) tumor burden. The methods of the present disclosure also include a step of (3) making a treatment decision based on the assessment. Additional embodiments of the present disclosure pertain to systems for assessing glioma in a subject.

This invention relates to the application of AMPA receptor antagonists in the preparation of drugs for treating peritoneal metastases of gastric cancer, belonging to the field of biomedical technology. This invention discloses the application of GRIA2 as a drug target in the preparation of drugs for the prevention or treatment of peritoneal metastases of gastric cancer. It discloses the use of AMPA receptor antagonists NBQX and / or Selurampanel in the preparation of drugs for the prevention or treatment of peritoneal metastases of gastric cancer. NBQX and Selurampanel can significantly inhibit the migration, invasion, spheroidization ability, and adhesion to mesothelial cells of gastric cancer cells; in vivo experiments have confirmed that AMPA receptor antagonists can significantly reduce tumor burden and the number of metastatic nodules in a mouse model of peritoneal metastases of gastric cancer. Patient-derived organoid xenograft models further demonstrate that AMPA receptor antagonists have significant efficacy against peritoneal metastases of gastric cancer with high GRIA2 expression. This invention provides a new treatment strategy for peritoneal metastases of gastric cancer.

The present disclosure provides technologies for target entity detection. One aspect of the present disclosure provides technologies for detection (e.g., early detection) of a disease, disorder, or condition (e.g., cancer). In another aspect, technologies provided herein are useful for selecting and / or monitoring and / or evaluating efficacy of, a treatment administered to a subject in need thereof, e.g., a subject determined to have or susceptible to cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics.

This invention relates to the preparation and application of an oncolytic virus that specifically promotes the rupture of tumor cell plasma membranes. Specifically, this invention utilizes a glioblastoma-specific Nestin enhancer or a tumor cell-specific Survivin promoter to drive the specific expression of the NINJ1 or DTA gene, thereby enhancing the lytic and killing ability of cells. The oncolytic virus G005 expressing NINJ1 exhibits strong killing ability against tumor cells, and the tumor completely disappears in an orthotopic glioma animal model. It can also rapidly restore the weight loss in mice caused by tumor burden, demonstrating that the oncolytic virus G005 has excellent therapeutic effects against GBM.

The application discloses a probe set for evaluating systemic tumor burden of pancreatic cancer and application thereof, wherein the probe set comprises probes for detecting gene markers, the gene markers comprising KRAS, TP53, CDKN2A, SMAD4, RNF43, TGFBR2, PIK3CA, BRAF, GNAS and CTNNB1, covering high-frequency and drug-related sites of pancreatic cancer, and the systemic tumor burden of a pancreatic cancer patient is monitored in real time and dynamically by performing targeted capture on plasma ctDNA alone or in combination with a personalized probe set.

This application belongs to the field of biomedical technology, specifically relating to the use of an ACSL4 inhibitor in the preparation of a drug for treating acute myeloid leukemia (AML). This application discloses for the first time the novel use of an ACSL4 inhibitor in the preparation of a drug for treating AML. In vitro experiments show that the ACSL4 inhibitor can effectively inhibit AML cell proliferation and promote apoptosis, without significantly affecting peripheral blood mononuclear cells in healthy controls. Animal experiments further confirm that the ACSL4 inhibitor can significantly delay disease progression in IGF2BP3-overexpressing AML mice, reduce tumor burden, and prolong the survival of NCG mice, further confirming its anti-leukemic effect in vivo.

Provided is a recombinant VAR2CSA protein, and a preparation method and use thereof. The provided recombinant VAR2CSA protein and the preparation method thereof feature high stability and high yield, as well as good efficiency and capacity in detecting oncofetal chondroitin sulfate (ofCS) and an oncofetal chondroitin sulfate proteoglycan (ofCSPG), can be used for large-scale production of proteins for detection of ofCS / ofCSPG, and are used for early screening, diagnosis, tumor burden monitoring, and prognosis prediction of malignant tumors.